Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 浙江昂利康制药股份有限公司是一家集医药原料药和药物制剂为一体，以口服头孢类、心血管类和肾病类药品为特色的现代化制药企业。公司拥有浙江昂利康胶囊有限公司、浙江昂利泰制药有限公司、江苏悦新药业有限公司、浙江昂博生物工程有限公司、浙江康云华鹏制药有限公司、浙江昂利康医药销售有限公司六家控股子公司。 公司坚持以质量为企业发展的基石，已建立了完善的质量管理体系，涵盖了从产品研发、原辅料采购、生产与质量控制、仓储、产品发行到销售追踪的全过程，并按照GMP规范制定了高于国家法定标准的公司内控质量标准，确保产品质量。 公司坚持以研发创新为企业发展的动力，作为国家高新技术企业，依托浙江省重点企业研究院、省级企业技术中心、院士专家工作站、外国专家工作站及博士后工作站等卓越的研发平台，不断推进自主研发，目前已成功积累了一大批核心技术，并拥有各类专业人才的优秀研发团队，为公司实现药物的自主研发奠定了丰厚的基础，实现从仿制到仿创，从仿创到创新的跨越。 公司注重业内合作，以至诚的信念竭力为上下游合作伙伴创造更大价值，不仅在产品上与美福润、宁波三元、珠海友邦等开展合作生产，在新产品布局上与万鹏朗格、苏州晶云、泓博智源等开展合作研发，也与海归研发团队共建平台开展对创新药物领域的探索，更与世界五百强德国费森尤斯卡比、国内药企龙头广药白云山等业内领先者成立合资公司，与众多国内外同行从竞争走向合作，共享医药前沿的技术与市场。 公司以社会责任为第一使命，积极投身于关爱弱势群体，会同嵊州市红十字会发起成立了“浙江昂利康·白血病救助基金”，部分困难家庭已经得到救助；并且积极参与精准扶贫，同龙游县罗家乡缪家村结对帮扶；在公司治理、安全经营、绿色发展、社会事务等诸多方面也持续努力，致力于实现和谐与共赢，体现昂利康人的责任与情怀。 着眼未来，公司将继续专注医药产业，整合内外资源，以上市为契机，加大技改投入和研发创新，秉承“诚信、激情、专业、尊重、合作”的价值观，以“健康发展、行业百强”为愿景，把公司建设成为行业内具有较强综合竞争力的创新型国际化医药企业。
Main Business 为医药的生产制造业务，主要包括化学原料药、化学制剂、药用辅料及特色中间体系列产品的研发、生产和销售。
Legal Representative 方南平
Top Executives
董事长：方南平
副董事长：吕慧浩
董事：郑国钢,吴哲华,吕慧浩
独立董事：赵秀芳,莫卫民,游剑
Top 5 Shareholder
Shareholder name Nature Holding Date
嵊州市君泰投资有限公司流通A股35.44%04/11/2024
方南平限售股+流通A股5.52%04/11/2024
吕慧浩限售股+流通A股3.60%04/11/2024
浙江昂利康制药股份有限公司－第一期员工持股计划流通A股2.15%04/11/2024
杨国栋限售股+流通A股1.44%04/11/2024
Company Secretary 孙黎明
Solicitors 浙江天册律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 0575-83100181
Fax No 0575-83100181
Website www.alkpharm.com
Email ir@alkpharm.com
Company Address
Register: 浙江省嵊州市嵊州大道北1000号
Office: 浙江省嵊州市嵊州大道北1000号
Listing Date 23/10/2018
Shares Capital
Shares Capital: 201,728,186
Total A Share: 201,728,186
Listed A Share: 185,275,467
Non-tradable A Share: 16,452,719
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.690
DPS(RMB)* ¥ 0.210
NBV Per Share(RMB)* ¥ 7.863
Market Capitalization(RMB) 2.518B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.